FDA Approves Lirafugratinib for FGFR2 Fusion Cholangiocarcinoma
FDA Approves Lirafugratinib for FGFR2 Fusion Cholangiocarcinoma Oncology News Central
2026
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration CancerNetwork
FDA Approves Lyrfigtu for Previously Treated FGFR2-Positive Cholangiocarcinoma
FDA Approves Lyrfigtu for Previously Treated FGFR2-Positive Cholangiocarcinoma Cure Today
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma ascopost.com
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma Oncology Nursing News